ロード中...
Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...
保存先:
| 出版年: | Clin Epidemiol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5312705/ https://ncbi.nlm.nih.gov/pubmed/28228662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S124674 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|